Table 4. Results of sub-group analysis for prevalence of CHIKV infection among children based on continent, study setting, diagnostic technique, study design and season.
| Subgroup analyses | |||
|---|---|---|---|
| Number of studies | Proportion in % (95% CI) | I2, % | |
| Continent | |||
| Africa | 17 | 8.86 [4.42; 16.98] | 97.2 |
| Asia | 20 | 8.78 [3.87; 18.70] | 97.8 |
| North America | 6 | 22.20 [4.22; 64.89] | 99.3 |
| South America | 10 | 22.83 [7.50; 51.88] | 92.5 |
| Study setting | |||
| Hospital/health centre | 37 | 13.02 [7.36; 21.99] | 98.1 |
| Community | 11 | 10.11 [4.38; 21.64] | 98.1 |
| Unspecified | 5 | 7.52 [0.68; 49.25] | 91.3 |
| Diagnostic technique | |||
| Detection of anti-CHIKV IgM | 19 | 11.09 [6.11; 19.31] | 97.3 |
| Detection of CHIKV RNA | 22 | 14.64 [6.64; 29.27] | 97.7 |
| Detection of anti-CHIKV IgM and CHIKV RNA | 12 | 8.56 [2.42; 26.12] | 98.4 |
| Study design | |||
| Longitudinal | 22 | 11.84 [5.14; 24.96] | 98.5 |
| Cross-sectional | 21 | 8.75 [4.65;15.88] | 97.4 |
| Unspecified | 10 | 21.08 [8.46; 43.55] | 95.5 |
| Season | |||
| Epidemic | 27 | 18.46 [10.52; 30.37] | 98.4 |
| Non-epidemic | 6 | 3.86 [1.91; 7.62] | 89.7 |
| Epidemic/Non-epidemic | 1 | 8.36 [5.97; 11.58] | NA |
| Unspecified | 19 | 8.59 [3.36; 20.23] | 96.7 |